[go: up one dir, main page]

MA40706A1 - Pyrrolopyrimidines et pyrazolopyrimidines utilisées en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7 - Google Patents

Pyrrolopyrimidines et pyrazolopyrimidines utilisées en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7

Info

Publication number
MA40706A1
MA40706A1 MA40706A MA40706A MA40706A1 MA 40706 A1 MA40706 A1 MA 40706A1 MA 40706 A MA40706 A MA 40706A MA 40706 A MA40706 A MA 40706A MA 40706 A1 MA40706 A1 MA 40706A1
Authority
MA
Morocco
Prior art keywords
inhibitors
pyrrolopyrimidines
pyrazolopyrimidines
ubiquitin
diseases
Prior art date
Application number
MA40706A
Other languages
English (en)
Inventor
Ann-Marie Campbell
R Bruce Diebold
Anna Ericsson
Stephanos Ioannidis
Adam Charles Talbot
Bruce Follows
Alexandre Joseph Buckmelter
Minghua Wang
Darby Rye Schmidt
David Joseph Guerin
Justin A Caravella
Lancia, Jr
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MA40706A1 publication Critical patent/MA40706A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des inhibiteurs d'usp7 utiles dans le traitement de cancers, maladies neurodégénératives, troubles immunologiques, troubles inflammatoires, maladies cardiovasculaires, maladies ischémiques, maladies et infections virales, et maladies et infections bactériennes, lesdits inhibiteurs étant représentés par la formule : (i) dans laquelle m, n, x
MA40706A 2014-12-30 2015-12-29 Pyrrolopyrimidines et pyrazolopyrimidines utilisées en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7 MA40706A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098141P 2014-12-30 2014-12-30
PCT/US2015/067831 WO2016109515A1 (fr) 2014-12-30 2015-12-29 Pyrrolopyrimidines et pyrazolopyrimidines utilisées en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7

Publications (1)

Publication Number Publication Date
MA40706A1 true MA40706A1 (fr) 2018-02-28

Family

ID=55310894

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40706A MA40706A1 (fr) 2014-12-30 2015-12-29 Pyrrolopyrimidines et pyrazolopyrimidines utilisées en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7

Country Status (22)

Country Link
US (4) US9902728B2 (fr)
EP (2) EP3623372B1 (fr)
JP (1) JP6649388B2 (fr)
KR (1) KR102581827B1 (fr)
CN (1) CN107406451B (fr)
AR (1) AR103297A1 (fr)
AU (2) AU2015374170B2 (fr)
CA (1) CA2972797C (fr)
CL (1) CL2017001687A1 (fr)
CO (1) CO2017006997A2 (fr)
EA (1) EA038204B1 (fr)
EC (1) ECSP17049010A (fr)
ES (1) ES2768996T3 (fr)
IL (1) IL252773A0 (fr)
MA (1) MA40706A1 (fr)
MX (2) MX373788B (fr)
PH (1) PH12017501224A1 (fr)
SA (1) SA517381839B1 (fr)
SG (1) SG11201704897QA (fr)
TW (2) TWI770525B (fr)
WO (1) WO2016109515A1 (fr)
ZA (1) ZA201704746B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087760A1 (es) 2011-09-02 2014-04-16 Incyte Corp Heterociclilaminas como inhibidores de pi3k
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン
JP2018504431A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン
EP3253759A1 (fr) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, et pyrrolopyrimidinones, en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7
PT3831833T (pt) 2015-02-27 2023-02-06 Incyte Corp Processos para a preparação de um inibidor pi3k
AU2017222958B2 (en) * 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
WO2017201683A1 (fr) * 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Composés de tétrahydroisoquinoline substitués utiles à titre d'agonistes de gpr120
CU20180146A7 (es) 2016-06-10 2019-07-04 Servier Lab Compuestos derivados de (piperidin-1-ilo)(piperidin-4-ilo) sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen
FR3061177B1 (fr) * 2016-12-28 2019-09-27 Les Laboratoires Servier Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR3052452B1 (fr) * 2016-06-10 2018-06-22 Les Laboratoires Servier Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018009812A1 (fr) 2016-07-08 2018-01-11 Mayo Foundation For Medical Education And Research Procédés et matériaux de traitement du cancer
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
SG10202104386UA (en) 2016-10-28 2021-05-28 Icahn School Med Mount Sinai Compositions and methods for treating ezh2-mediated cancer
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
CN108239082B (zh) * 2016-12-26 2021-01-05 成都先导药物开发股份有限公司 一种抑制rock的化合物及其应用
MA49017A (fr) 2017-03-21 2020-02-05 Univ Temple Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques
WO2018175188A1 (fr) * 2017-03-21 2018-09-27 Temple University-Of The Commonwealth System Of Higher Education Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation
US11512067B2 (en) 2017-09-14 2022-11-29 Daiichi Sankyo Company, Limited Compound having cyclic structure
WO2019084030A1 (fr) 2017-10-24 2019-05-02 Genentech, Inc. Composés de (4-hydroxypyrrolidin-2-yl)-hydroxamate et leurs procédés d'utilisation
EP3700901A1 (fr) 2017-10-24 2020-09-02 Genentech, Inc. Composés (4-hydroxypyrrolidin-2-yl)-hétérocycliques et leurs procédés d'utilisation
US11332472B2 (en) * 2017-11-29 2022-05-17 Les Laboratoires Servier Substituted piperidines as inhibitors of ubiquitin specific protease 7
DK3724191T3 (da) 2017-12-15 2022-03-14 Pyramid Biosciences Inc 5-(2-(2,5-difluorphenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazol[1,5-a]pyrimidinderivater og lignende forbindelser som trk-kinasehæmmere til cancerbehandling
RU2020124116A (ru) 2017-12-22 2022-01-25 Хиберселл, Инк. Производные арил-бипиридинамина в качестве ингибиторов фосфатидилинозитолфосфаткиназы
GB201801562D0 (en) 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
CA3092677A1 (fr) 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Composes de degradation/interruption de serine threonine kinase (akt) et procedes d'utilisation
WO2019183523A1 (fr) 2018-03-23 2019-09-26 Genentech, Inc. Composés de dégradation hétéro-bifonctionnels et leur utilisation en tant que modulateurs de l'ubiquination ciblée (vhl)
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
SG11202010068VA (en) 2018-04-25 2020-11-27 Bayer Ag Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
US12110295B2 (en) 2018-06-21 2024-10-08 Icahn School Of Medicine At Mount Sinai WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
JP7508449B2 (ja) 2018-10-22 2024-07-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｕｓｐ７の阻害
CN113365696A (zh) * 2018-12-06 2021-09-07 阿尔麦克探索有限公司 药物化合物和其作为泛素特异性蛋白酶19(usp19)抑制剂的用途
KR102712818B1 (ko) 2018-12-06 2024-09-30 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
MX2021006542A (es) * 2018-12-06 2021-07-07 Almac Discovery Ltd Inhibidores de la usp19 para usarse en terapia.
CN109666005A (zh) * 2018-12-14 2019-04-23 上海毕得医药科技有限公司 一种2-溴恶唑-5-甲酸乙酯的合成方法
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
WO2020142557A1 (fr) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibiteurs irréversibles de l'interaction ménine-mll
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
EP3923987A1 (fr) 2019-02-14 2021-12-22 Institut National de la Santé et de la Recherche Médicale (INSERM) Utilisation d'inhibiteurs de l'usp7 pour le traitement de la leucémie aiguë myéloïde (lam)
CN109912598B (zh) * 2019-03-27 2022-09-13 四川大学华西医院 防治炎症反应的核苷类衍生物及其应用
WO2020207352A1 (fr) * 2019-04-11 2020-10-15 四川科伦博泰生物医药股份有限公司 Composés de benzimidazole triazine et leur utilisation médicale
EP3965824B1 (fr) 2019-05-06 2025-01-08 Icahn School of Medicine at Mount Sinai Composés hétérobifonctionnels en tant qu'agents de dégradation de hpk1
CN112608320B (zh) * 2020-01-16 2023-03-17 中国药科大学 哌啶类化合物及其制备方法和医药用途
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
EP4135700A4 (fr) * 2020-04-15 2024-04-17 Pyramid Biosciences, Inc. Procédés de préparation d'inhibiteurs de récepteurs à activité tyrosine kinase
KR20220162155A (ko) 2020-04-27 2022-12-07 주식회사 오토텍바이오 Ubr 박스 도메인 리간드로의 화합물
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
UY39391A (es) * 2020-08-24 2022-03-31 Adama Makhteshim Ltd Proceso para la preparación de pirazoles sustituidos
WO2022159650A1 (fr) * 2021-01-22 2022-07-28 Icahn School Of Medicine At Mount Sinai Composés hétérobifonctionnels utilisés en tant qu'agents de dégradation de l'eef1a2
AU2022234302A1 (en) 2021-03-10 2023-10-12 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc6a19 function
CN117412973A (zh) * 2021-05-31 2024-01-16 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
WO2023004291A1 (fr) * 2021-07-19 2023-01-26 Baylor College Of Medicine Inhibiteurs de protéase principale du coronavirus et leurs méthodes d'utilisation
JP2024526849A (ja) * 2021-07-20 2024-07-19 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ユビキチン特異的プロテアーゼ７（ｕｓｐ７）を標的とする阻害剤
EP4384179A1 (fr) 2021-08-11 2024-06-19 Biomea Fusion, Inc. Inhibiteurs covalents de l'interaction ménine-mll pour le diabète sucré
CN119816500A (zh) 2021-08-20 2025-04-11 拜欧米富士恩公司 用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式
GB202200753D0 (en) 2022-01-21 2022-03-09 Almac Discovery Ltd Pharmaceutical compounds
CN114957248B (zh) * 2022-05-09 2023-12-29 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
WO2024155710A1 (fr) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Formes cristallines de n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phényl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-pipéridinyl]méthyl]-2- pyridinecarboxamide en tant qu'inhibiteur covalent de l'interaction ménine-mll
EP4467535A1 (fr) 2023-05-25 2024-11-27 Basf Se Composés pesticides à base de lactame
WO2024240859A1 (fr) 2023-05-25 2024-11-28 Basf Se Composés pesticides à base de lactame
TW202515554A (zh) * 2023-08-11 2025-04-16 美商杰那醫療公司 Slc6a19功能之含雙環雜芳基之哌啶抑制劑
CN118496138B (zh) * 2024-07-10 2024-12-03 西北农林科技大学深圳研究院 一种l-氮杂环丁烷-2-羧酸的合成方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6008217A (en) 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5985863A (en) 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
IN151496B (fr) 1980-02-26 1983-05-07 Chamanlal Jagannath Shishoo
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2777159B2 (ja) 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
US5124335A (en) 1991-01-30 1992-06-23 Merck & Co., Inc. Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US20120165319A1 (en) 1995-12-20 2012-06-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
JP2001524121A (ja) 1997-05-08 2001-11-27 アグレボ・ユー・ケイ・リミテツド 殺菌剤
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
EP1073643B1 (fr) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. Nouveaux composes heterocycliques, leur utilisation en medecine, leur procede de preparation et compositions pharmaceutiques les contenant
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US20030153598A1 (en) 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
US20060183776A9 (en) 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
DE60124730T2 (de) 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
DE60105020T2 (de) 2000-06-07 2005-08-18 Almirall-Prodesfarma S.A. 6-phenylpyrrolopyrimidindion derivate
US6506771B2 (en) 2000-06-23 2003-01-14 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl heterobicyclic factor Xa inhibitors
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
PE20020394A1 (es) * 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
US20020169175A1 (en) 2001-02-05 2002-11-14 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of heterocyclic compounds
US6960595B2 (en) 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
WO2003024456A1 (fr) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methodes de traitement et de prevention des migraines
AU2002340232A1 (en) 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
WO2003076400A1 (fr) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Nouveaux inhibiteurs de l'histone deacetylase
GB2405336A (en) 2002-05-01 2005-03-02 Eisai Co Ltd Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2004034963A2 (fr) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methodes et compositions utilisant des inhibiteurs de la cholinesterase
US20070053976A1 (en) 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
WO2004014916A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs bicycliques condenses de metalloproteinases de type pyrimidine
WO2004014908A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloproteinases heterobicycliques
AU2003301662A1 (en) * 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
ES2289377T3 (es) 2003-03-18 2008-02-01 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Nuevas pirazolopirimidonas y su uso como inhibidores de pde.
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
US7557113B2 (en) 2003-08-26 2009-07-07 Teijin Pharma Limited Substituted pyrrolo[3,2-d]pyrimidine derivatives
PE20050347A1 (es) 2003-08-26 2005-05-04 Teijin Pharma Ltd Derivados de pirrolopirimidina
US20050187147A1 (en) 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
US20050148534A1 (en) 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US7868205B2 (en) 2003-09-24 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
WO2005087226A1 (fr) 2004-03-05 2005-09-22 Eisai Co., Ltd. Traitement de cadasil avec des inhibiteurs de la cholinesterase
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
EP1737831B1 (fr) 2004-04-02 2013-05-22 Prana Biotechnology Limited Composes neurologiquement actifs
US20080045500A1 (en) 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
US20060135507A1 (en) 2004-08-13 2006-06-22 Osamu Yokoyama Therapeutic agent for overactive bladder involved in aging
US20060172992A1 (en) 2004-08-13 2006-08-03 Eisai Co., Ltd. Therapeutic agent for overactive bladder resulting from cerebral infarction
NZ553087A (en) 2004-08-31 2010-12-24 Astrazeneca Ab Quinazolinone derivatives and their use as B-raf inhibitors
WO2007053135A1 (fr) * 2004-09-14 2007-05-10 Minerva Biotechnologies Corporation Méthodes de diagnostic et de traitement du cancer
JP2006176503A (ja) 2004-11-26 2006-07-06 Tohoku Univ 脳血管障害を伴うアルツハイマー病治療薬
RU2382786C2 (ru) 2004-12-24 2010-02-27 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Бициклические производные пиррола
EP1876179B1 (fr) 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Composés de thiénopyrimidone
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
BRPI0620643A2 (pt) 2005-12-23 2011-12-20 Novartis Ag compostos de heterocìclicos condensados úteis como inibidores de dpp-iv, formulações farmacêuticas, produtos e usos dos compostos
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
WO2008094909A2 (fr) 2007-01-29 2008-08-07 Xenon Pharmaceuticals Inc. Composés de quinazolinone et de pyrimidinone fusionnés et leur utilisation dans le traitement de maladies ou d'affections induites par les canaux sodiques
WO2008112715A2 (fr) 2007-03-12 2008-09-18 Vm Discovery Inc. Nouveaux agents modulateurs des canaux d'ions calcium
WO2008113255A1 (fr) 2007-03-16 2008-09-25 The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques
WO2008116053A2 (fr) * 2007-03-20 2008-09-25 Trustees Of Tufts College Composés chimiothérapeutiques activés par la protéine fap
WO2008138126A1 (fr) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Dérivés bicycliques de pyrimidine en tant que bloqueurs des canaux calciques
RU2341527C1 (ru) 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
RU2345996C1 (ru) 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
WO2009068617A1 (fr) * 2007-11-30 2009-06-04 Boehringer Ingelheim International Gmbh Dérivés de 1,5-dihydro-pyrazolo(3,4-d)pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a pour le traitement de troubles du snc
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CA2719362A1 (fr) 2008-04-04 2009-10-08 Gilead Sciences, Inc. Derives de pyrrolotriazinone pouvant etre utilises a titre d'inhibiteurs de stearoyl-coa desaturase
CA2737219C (fr) 2008-08-11 2017-02-28 Tracy Keller Analogues d'halofuginone pour l'inhibition d'arnt synthetases et leurs utilisations
US20110082158A1 (en) 2008-10-01 2011-04-07 Aleem Gangjee Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
AU2009329879A1 (en) 2008-12-23 2011-08-11 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US8927718B2 (en) 2009-08-26 2015-01-06 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
EP2488520B1 (fr) 2009-10-13 2015-09-02 Merck Sharp & Dohme B.V. Dérivés d'azines condensés pour le traitement de maladies liées au recepteur d'acetylcholine
WO2011097607A1 (fr) 2010-02-08 2011-08-11 Southern Research Institute Traitement antiviral et dosage pour cribler des antiviraux
US8575114B2 (en) 2010-03-23 2013-11-05 Albany Molecular Research, Inc. SGLT-2 inhibitors, methods of making them, and uses thereof
WO2012054332A1 (fr) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Acides hydroxamiques substitués et leurs utilisations
WO2012075393A2 (fr) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activateurs de la dégradation protéasomique et leurs utilisations
EP2663311A2 (fr) 2011-01-10 2013-11-20 GlaxoSmithKline LLC Dérivés de pyrimidinone en tant qu'inhibiteurs de l'acide gras synthase
GB201107768D0 (en) 2011-05-10 2011-06-22 Univ Manchester Riboswitches
EP2565186A1 (fr) * 2011-09-02 2013-03-06 Hybrigenics S.A. Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
TW201348226A (zh) 2012-02-28 2013-12-01 Amgen Inc 作為ｐｉｍ抑制劑之醯胺
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
US9802904B2 (en) 2012-12-28 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
KR101446680B1 (ko) 2013-02-08 2014-10-07 한국과학기술연구원 ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체
CN103833646A (zh) 2014-02-28 2014-06-04 广东工业大学 一种脂肪氨基取代喹唑啉酮衍生物及其制备方法和应用
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
JP2018504431A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン
EP3253759A1 (fr) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, et pyrrolopyrimidinones, en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン

Also Published As

Publication number Publication date
US12018030B2 (en) 2024-06-25
EA201791507A1 (ru) 2018-01-31
ES2768996T3 (es) 2020-06-24
AU2015374170A1 (en) 2017-07-27
EP3623372A1 (fr) 2020-03-18
EP3623372B1 (fr) 2026-02-04
TWI698436B (zh) 2020-07-11
CA2972797C (fr) 2023-12-05
SA517381839B1 (ar) 2022-05-30
TW202115067A (zh) 2021-04-16
US20160185785A1 (en) 2016-06-30
KR20170106981A (ko) 2017-09-22
MX2017008604A (es) 2017-11-15
CN107406451B (zh) 2019-12-17
EA038204B1 (ru) 2021-07-22
US10934299B2 (en) 2021-03-02
AU2015374170B2 (en) 2020-10-22
JP2018500376A (ja) 2018-01-11
US20180339988A1 (en) 2018-11-29
AR103297A1 (es) 2017-05-03
EP3240791A1 (fr) 2017-11-08
US10377760B2 (en) 2019-08-13
MX373788B (es) 2020-03-23
WO2016109515A1 (fr) 2016-07-07
KR102581827B1 (ko) 2023-09-25
CN107406451A (zh) 2017-11-28
EP3240791B1 (fr) 2019-11-06
IL252773A0 (en) 2017-08-31
JP6649388B2 (ja) 2020-02-19
CA2972797A1 (fr) 2016-07-07
PH12017501224A1 (en) 2018-01-15
HK1246284A1 (zh) 2018-09-07
ZA201704746B (en) 2025-10-29
TWI770525B (zh) 2022-07-11
ECSP17049010A (es) 2017-11-30
US20190367525A1 (en) 2019-12-05
CO2017006997A2 (es) 2017-10-20
SG11201704897QA (en) 2017-07-28
US20210332052A1 (en) 2021-10-28
US9902728B2 (en) 2018-02-27
CL2017001687A1 (es) 2018-03-23
BR112017013692A2 (pt) 2018-01-09
MX2020002963A (es) 2020-07-22
AU2021200346A1 (en) 2021-03-18
TW201639847A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
MA40706A1 (fr) Pyrrolopyrimidines et pyrazolopyrimidines utilisées en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7
HK1246285A1 (zh) 作为泛素特异性蛋白酶7(usp7)抑制剂用於治疗癌症的吡咯并三嗪酮和咪唑并三嗪酮衍生物
HK1248221A1 (zh) 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
MA41013A (fr) Compositions comprenant des souches bactériennes
HK1248222A1 (zh) 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂
MX379543B (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
HK1248220A1 (zh) 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
MX385332B (es) Moduladores de ror-gamma.
MX383213B (es) Inhibidores de tirosina-cinasas
MX2016002238A (es) Alcoholes de alquilino y metodos de uso.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
WO2016127179A3 (fr) Agents immunomodulateurs
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
MX382624B (es) Compuestos farmacéuticos.
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
WO2016057413A3 (fr) Inhibiteurs de lysine gingipaïne
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
CA3010708A1 (fr) Procedes d'administration d'hepcidine
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
WO2015198263A3 (fr) Nouveaux dérivés substitués par proline bétulinique utilisés comme inhibiteurs du vih
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives